Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QH103 in Relapsed/Refractory CD19-positive B-ALL
NCT07491263Phase 1Not yet recruiting
- Sponsor
- Fujian Medical University
- Start
- May 2026
- Primary completion
- Apr 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QH103E in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Fujian Medical University. Primary endpoints: Adverse Events at 12 months and Incidence of Dose-Limiting Toxicities at 28 days. Planned start May 2026; status: not yet recruiting.
02
Drugs
QH103E
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07491263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07491263.